Home | Coriolis Pharma

Coriolis Pharma Formulating innovation

For us innovation is progress achieved by collaboration. We generate innovation by combining technologies, knowledge and experience.

Formulating for us means to find the right solution.

About us

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.

As a family-owned and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our customers.

Formulation Development

“It is a medicine, not a molecule, that we are giving to the patient” Marc B. Brown, 2005.

Coriolis is the expert in developing liquid and lyophilized formulations for a large variety of different (bio)pharmaceutical molecules.

Find out how we can support your drug development...

Analytical Capabilities

A highly diverse analytical portfolio entirely performed in-house: This is Coriolis.

With the latest in technology and highly experienced scientists, we are a trendsetter in the field.

Get to know our services...

About us

Independent, reliable and always on the cutting edge of science. Coriolis is the leading service provider for formulation research and development of (bio)pharmaceutical drugs and vaccines.

Get to know us...

Latest news

2020/02/11

Coriolis will be present at Freeze-Drying Summit in Vienna

2020/01/30

Coriolis advisor gives talk at LAII Conference in La Jolla

2020/01/28

Coriolis CSO discusses excipients for parenterals at IPEC Forum

2020/01/27

Coriolis (co-)authored 14 scientific publications in 2019

2020/01/10

Coriolis celebrates “two giants”: Prof. Carpenter and Prof. Randolph

2020/01/09

Coriolis participates at PepTalk event in San Diego

2019/12/20

Coriolis spreads the Christmas spirit

2019/11/15

Coriolis scientific advisor to give Keynote Presentation at PEGS Europe

2019/11/13

Coriolis co-organizes workshop on protein stability

2019/11/11

Coriolis scientific advisor speaks at MIBio in Cambridge, UK

View all

Latest publications

Exploring Chemical Space for New Substances to Stabilize a Therapeutic Monoclonal Antibody.

Tosstorff A, Menzen T, Winter G.

Taking subvisible particle quantitation to the limit: Uncertainties and statistical challenges with ophthalmic products for intravitreal injection.

Gühlke M, Hecht J, Böhrer A, Hawe A, Nikels F, Garidel P, Menzen T.

Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life Cycle.

Mathaes R, Narhi L, Hawe A, Matter A, Bechtold-Peters K, Kenrick S, Kar S, Laskina O, Carpenter J, Cavicchi R, Koepf E, Lewis EN, De Silva R, Ripple D.

Factors Influencing Polysorbate's Sensitivity Against Enzymatic Hydrolysis and Oxidative Degradation.

Kranz W, Wuchner K, Corradini E, Berger M, Hawe A.

Intrinsic Differential Scanning Fluorimetry for Fast and Easy Identification of AAV Serotypes.

Rieser R, Penaud-Budloo M, Bouzelha M, Rossi A, Menzen T, Biel M, Büning H, Ayuso E, Winter G, Michalakis S.

Novel high-throughput assay for polysorbate quantification in biopharmaceutical products by using the fluorescent dye DiI.

Martos A, Berger M, Kranz W, Spanopoulou A, Menzen T, Friess W, Wuchner K, Hawe A.

What makes polysorbate functional? Impact of polysorbate 80 grade and quality on IgG stability during mechanical stress.

Grabarek AD, Bozic U, Rousel J, Menzen T, Kranz W, Wuchner K, Jiskoot W, Hawe A.

Stress Factors in Monoclonal Antibody Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy.

Das TK, Narhi LO, Sreedhara A, Menzen T, Grapentin C, Chou DK, Antochshuk V, Filipe V.

Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences

Crommelin D, Nastribattusta E, Hawe A, Hoogendoorn K and Jiskoot W.

Immunogenicity of therapeutic proteins.

Jiskoot W, Rispens T and Kijanka G.

View all